IBA remains fully operational during the COVID-19 crisis.

Corporate
/
06.04.2020
First of all, we would like to address a special “thank you” to all healthcare professionals as they continue working in increasingly dangerous conditions while offering high-end cancer diagnosis and therapies in an overwhelmed healthcare system. We want to showcase you and thank you for the hard work you do every day.
During this time of great uncertainty and unprecedented change due to the COVID-19 pandemic, IBA’s commitment to all its customers remains stronger than ever. While we recognize these unique challenges, all IBA Teams remain dedicated to fully assisting your needs as you continue your crucial work of helping patients.
If you need to contact us, the usual channels remain unchanged. As a reminder, here are the different primary email addresses.
Customer support
- Proton Therapy Customer support: use your usual contact
- RadioPharma Solutions Customer support: customer_support@iba-group.com
- Industrial and Sterilization Customer support: customer_support@iba-group.com
- Dosimetry
USA, Canada, Latin America
eMail: service-usa@iba-group.com
Europe, Middle East, Africa
eMail: service-emea@iba-group.com
Asia Pacific, Australia, New Zealand
eMail: service-apac@iba-group.com
General Contact
- Contact RadioPharma Solutions: Radiopharmasolutions@iba-group.com
- Contact Dosimetry Solutions: dosimetry-info@iba-group.com
- Contact Proton Therapy Solutions: info-pt@iba-group.com
- Contact Industrial and sterilization Solutions: industrial.eu@iba-group.com
- IBA Group: info-worldwide@iba-group.com
IBA operates worldwide and in many geographies that are being impacted by the COVID-19 outbreak. This very same geographical spread allows the Group to mitigate the impact of the crisis to some extent, as countries are in varying stages of management of the outbreak.
IBA continues to monitor the situation very closely in order to protect its employees, its customers and their patients while ensuring the least possible disruption to its activities.